The Food and Drug Administration (FDA) is considering adding a black box warning regarding the use of antidepressants during pregnancy, raising concerns among healthcare providers. They fear such a warning could deter pregnant individuals from pursuing necessary treatment.
FDA Commissioner Marty McCurry hosted a panel to discuss the safety of antidepressants, especially serotonin reuptake inhibitors (SSRIs). Some participants questioned the established scientific views on these medications.
While doctors acknowledge that there might be some risks associated with SSRIs during pregnancy, they assert that the dangers of untreated mood disorders are often much more severe.
The American College of Obstetricians and Gynecologists (ACOG) released a statement calling the discussion “Surprisingly Unbalanced.”
The ACOG criticized the panel for sharing unsubstantiated claims, arguing they could incite undue fear and lead to patients avoiding the treatment they require.
Panelists raised concerns about improving warnings related to the potential risks of drugs to a developing fetus, suggesting changes to current antidepressant labels.
In his introductory comments, McCully emphasized that certain medications could influence the development of vital organs, including the brain and heart. He mentioned that SSRIs are linked to various studies that examine their impact on postnatal complications and cognitive issues.
One panelist, Annick Bellard from the University of Montreal, presented evidence that SSRIs like paroxetine and fluoxetine might significantly heighten the risks of adverse health outcomes, such as miscarriage and low birth weight.
For instance, Bellard noted that the absolute risk of miscarriage could increase from about 6% to 10% when SSRIs are taken during pregnancy.
“It’s crucial to discuss these risks openly when caring for pregnant patients dealing with depression or anxiety,” she stated.
Some medical professionals criticized the panel’s perspective, arguing it was one-sided, as just one of ten participants spoke in favor of SSRIs as a valuable treatment for anxiety and depression during pregnancy.
Tiffany Moore Simas, an OB-Gyn at UMass Memorial Health, expressed concern that the disproportionate focus of the discussion could further stigmatize the use of antidepressants among expectant mothers, asserting that SSRIs do not warrant a “black box” warning.
She noted that many people in perinatal care avoid medication out of fear of harming the fetus, and that this panel discussion might have exacerbated such fears.
A representative from the Department of Health and Human Services, which oversees the FDA, refrained from commenting on potential future policies about antidepressants. The spokesperson described it as “shaming” to imply that the expert panel was either biased or politically motivated.
The spokesperson defended Commissioner McCully’s commitment to integrating the latest scientific findings while focusing on public health.
Many individuals experience mental health challenges during pregnancy, with studies suggesting that around 20% of women may deal with depression or anxiety in this period.
Of those, approximately 8% resort to SSRIs as a treatment option. Untreated mental health conditions can lead to serious complications like premature birth and low birth weight, contributing significantly to maternal mortality rates in the U.S.
Research indicates that between 5% and 14% of pregnant or postpartum individuals may experience suicidal thoughts, with some estimates suggesting that suicide can account for 20% of deaths in the postnatal period.
While the decision to begin or continue SSRI treatment during pregnancy involves careful consideration, providers generally strive to minimize potential risks to the fetus.
This has led to recommending treatment as the first course of action for mild to moderate depression.
Nonetheless, there is strong evidence supporting the necessity of treating moderate to severe depression, which shows that using SSRIs doesn’t significantly raise the risk of birth defects.
Currently, there’s a baseline 3-5% risk of birth defects during pregnancy; however, data from the Centers for Disease Control and Prevention and various extensive studies over the past three decades indicate that SSRIs do not increase this risk.
Panelists acknowledged that organizations like ACOG had conducted studies without randomized trials to evaluate the safety of SSRIs, emphasizing this should be a priority.
However, doctors argued that the studies cited by the panelists lacked proper design and had inadequate controls. They stressed the importance of conducting thoroughly designed studies comparing outcomes between depressed individuals taking SSRIs and those who are not.
